Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Fisher & Paykel Healthcare Corp Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$17.81 billion
P/E Ratio
34.97
Dividend Yield
1.19%
Shares Outstanding
576.35 million
Earnings per share
0.904
Dividend per share
0.36
Year To Date Return
-2.89%
Earnings Yield
2.86%
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)
Latest News
Share Gainers
These ASX 200 healthcare shares are holding up in today’s sea of red
Broker Notes
Leading brokers name 3 ASX shares to sell today
Healthcare Shares
5 worst-performing ASX 200 healthcare shares of FY21
Broker Notes
Leading brokers name 3 ASX shares to sell today
Share Market News
ASX 200 Weekly Wrap: ASX record highs tumble like… Costa shares
Broker Notes
Top brokers name 3 ASX shares to sell next week
Broker Notes
Biggest ASX losers in May could be winners in June
Share Market News
These were the worst performing ASX 200 shares last week
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 10 Dec 2009 | $0.0429 | 0.00% | Interim | 18 Dec 2009 |
| 22 Jun 2009 | $0.0560 | 0.00% | Final | 06 Jul 2009 |
FPH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Fisher & Paykel Healthcare Corp Ltd
Fisher & Paykel Healthcare Corp Ltd (FPH) is a global designer and manufacturer of products and systems for use in a range of healthcare services. The company’s products are split into two groups: hospital and homecare.
In the hospital product group, Fisher & Paykel provides a range of humidification products such as ventilators and nasal high flow for adults and infants. Within homecare, Fisher & Paykel is a leading provider of CPAP devices and humidifiers for those who suffer from obstructive sleep apnea.
The overarching Fisher & Paykel company was established in 1934 as an importer of refrigerators and washing machines. The company’s involvement in healthcare began in 1969 when it looked to branch out and benefit from growing manufacturing and electronic expertise.
In 2001, the company split into two separate entities, healthcare and appliances. Today, Fisher & Paykel Healthcare reaches customers in more than 120 countries and its shares are listed on both the ASX and NZX.
FPH Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 23 Jul 2021 | $30.90 | $1.05 | 3.52% | 434,407 | $30.03 | $30.96 | $29.99 |
| 22 Jul 2021 | $29.85 | $-0.24 | -0.80% | 431,443 | $30.21 | $30.21 | $29.80 |
| 21 Jul 2021 | $30.09 | $0.27 | 0.91% | 446,824 | $29.92 | $30.17 | $29.81 |
| 20 Jul 2021 | $29.82 | $0.55 | 1.88% | 451,048 | $29.30 | $29.98 | $29.22 |
| 19 Jul 2021 | $29.27 | $0.55 | 1.92% | 436,168 | $28.73 | $29.40 | $28.65 |
| 16 Jul 2021 | $28.72 | $0.04 | 0.14% | 891,901 | $28.65 | $28.83 | $28.58 |
| 15 Jul 2021 | $28.68 | $-0.02 | -0.07% | 495,280 | $28.68 | $28.78 | $28.45 |
| 14 Jul 2021 | $28.70 | $0.20 | 0.70% | 412,863 | $28.29 | $28.84 | $28.13 |
| 13 Jul 2021 | $28.50 | $0.31 | 1.10% | 463,731 | $28.25 | $28.60 | $28.20 |
| 12 Jul 2021 | $28.19 | $0.04 | 0.14% | 460,624 | $28.21 | $28.37 | $28.03 |
| 09 Jul 2021 | $28.15 | $-0.05 | -0.18% | 300,799 | $28.00 | $28.15 | $27.63 |
| 08 Jul 2021 | $28.20 | $0.05 | 0.18% | 366,365 | $28.25 | $28.46 | $27.93 |
| 07 Jul 2021 | $28.15 | $-0.03 | -0.11% | 573,956 | $28.19 | $28.27 | $27.63 |
| 06 Jul 2021 | $28.18 | $-0.28 | -0.98% | 738,563 | $28.46 | $28.75 | $28.03 |
| 05 Jul 2021 | $28.46 | $0.11 | 0.39% | 299,194 | $28.48 | $28.69 | $28.41 |
| 02 Jul 2021 | $28.35 | $-0.25 | -0.87% | 369,508 | $28.62 | $28.63 | $28.21 |
| 01 Jul 2021 | $28.60 | $-0.32 | -1.11% | 445,881 | $28.90 | $29.02 | $28.60 |
| 30 Jun 2021 | $28.92 | $-0.65 | -2.20% | 643,419 | $29.59 | $29.66 | $28.81 |
| 29 Jun 2021 | $29.57 | $-0.25 | -0.84% | 370,317 | $29.76 | $29.84 | $29.36 |
| 28 Jun 2021 | $29.82 | $0.51 | 1.74% | 488,494 | $29.50 | $29.95 | $29.49 |
| 25 Jun 2021 | $29.31 | $-0.28 | -0.95% | 478,492 | $29.75 | $29.91 | $29.03 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 04 Mar 2021 | Scott St John | Buy | 500 | $14,025 |
As advised by the company. Purchase of Ordinary Shares
Trading in $NZD. |
| 27 Nov 2020 | Scott St John | Buy | 1 | $48,705 |
As advised by the company. Purchase of Ordinary Shares
Trading in $NZD. |
| 10 Sep 2020 | Lewis Gradon | Sell | 135 | $4,565,936 |
As advised by the company. Trading in $NZD.
Sale of 135,000 Ordinary Shares. |
| 10 Sep 2020 | Lewis Gradon | Issued | 22 | $684,191 |
Issue of securities. Trading in $NZD.
163,090 - PSRs |
| 10 Sep 2020 | Lewis Gradon | Issued | 64 | $1,992,848 |
Conversion of securities. Trading in $NZD.
|
| 10 Sep 2020 | Lewis Gradon | Exercise | 64 | $1,992,848 |
Conversion of securities. Trading in $NZD.
98,492 - PSRs |
| 08 Sep 2020 | Lewis Gradon | Issued | 73 | $2,299,251 |
Issue of securities. Trading in $NZD.
|
| 08 Sep 2020 | Lewis Gradon | Issued | 69 | $2,186,742 |
Issue of options. Trading in $NZD.
|
| 08 Sep 2020 | Lewis Gradon | Cancelled | 111 | $3,482,352 |
Cancellation of securities. Trading in $NZD.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael Grenfell Daniell | Non-Executive Director | Nov 2001 |
Mr Daniell is a member of the Council of the University of Auckland, a director of Cochlear Limited, Tait Limited and the Medical Research Commercialisation Fund, and Chair of the Medical Technologies Centre of Research Excellence. He is a member of Risk Committee.
|
| Mr Lewis George Gradon | Chief Executive OfficerManaging Director | Apr 2016 |
Mr Gradon during his 37-year tenure with Fisher & Paykel Healthcare he has held various engineering positions overseeing the development of our range of products as well the development of our manufacturing, quality, intellectual property, supply chain and clinical research functions.
|
| Mr Neville Mitchell | Non-Executive Director | Nov 2018 |
Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear Limited between 1995 and 2017. He is non-executive director of Sonic Healthcare, Osprey Medical and Q'Biotics Group, a member of the Australian Board of Taxation, and a director of the South East Sydney Local Health District Board. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing), for the Australian Securities and Investments Commission. He is a member of Quality, Safety and Regulatory Committee.
|
| Mr Donal Paul O'Dwyer | Non-Executive Director | Dec 2012 |
Mr O'Dwyer is a director of Cochlear Limited, Mesoblast Limited and nib Holdings Limited. From 1996 to 2003, he was with Cordis Cardiology, initially as its president (Europe) and from 2000 to 2003 as its worldwide president. He worked for 12 years with Baxter Healthcare, as a plant manager in Ireland & then president of the Cardiovascular Group, Europe, now Edwards Lifesciences. He is the chairman of Quality, Safety & Regulatory Committee and member of People Committee.
|
| Ms Geraldine Celia McBride | Non-Executive Director | Aug 2013 |
Ms McBride has been in the technology industry for 30 years and has global experience. She has held senior executive roles at SAP AG and Dell Inc, and is a former President of SAP North America. She is a director of National Australia Bank and Sky Network Television Ltd, and the founder and CEO of MyWave.
|
| Mr Antony (Tony) John Carter | Non-Executive DirectorNon-Executive Chairman | Dec 2010 |
Mr Gradon during his 37-year tenure with Fisher & Paykel Healthcare he has held various engineering positions overseeing the development of our range of products as well the development of our manufacturing, quality, intellectual property, supply chain and clinical research functions.
|
| Mr Scott Andrew St John | Non-Executive Director | Oct 2015 |
Mr Carter was managing director of Foodstuffs New Zealand Limited for ten years until his retirement in 2010. He is chairman of the board of TR Group and Datacom Group, a director of Vector Limited and ANZ Bank New Zealand Limited, and a trustee of the Maurice Carter Charitable Trust. He is a member of Quality, Safety & Regulatory, People and Risk Committee.
|
| Ms Philippa (Pip) Mary Greenwood | Non-Executive Director | Jun 2017 |
Ms Greenwood is a director of Spark New Zealand Limited, Westpac New Zealand Limited and a2 Milk Company Limited, a current trustee of the Auckland Writers Festival and served as a member of the New Zealand Takeovers Panel from 2007 to 2011. She was a partner at Russell McVeagh between 2001 and 2019 and previously served as the firm's Board Chair. She has advised on market transactions. She is the chairman of People Committee.
|
| Mr Marcus James Driller | Company SecretaryVice President - Corporate |
-
|
|
| Marcus James Driller | Company SecretaryVice President - Corporate |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Nominees (New Zealand) Limited | 84,735,040 | 14.70% |
| HSBC Nominees (New Zealand) Limited I | 66,978,951 | 11.62% |
| Jpmorgan Chase Bank | 58,909,933 | 10.22% |
| Citibank Nominees (Nz) Ltd | 41,810,783 | 7.25% |
| HSBC Custody Nominees (Australia) Limited | 39,770,963 | 6.90% |
| Jpmorgan Nominees Australia Pty Limited | 21,751,016 | 3.77% |
| Citicorp Nominees Pty Limited | 18,666,433 | 3.24% |
| Tea Custodians Limited | 15,191,575 | 2.64% |
| New Zealand Superannuation Fund Nominees Limited | 12,416,669 | 2.15% |
| National Nominees New Zealand Limited | 11,789,542 | 2.05% |
| Accident Compensation Corporation | 9,617,415 | 1.67% |
| BNP Paribas Nominees Nz Limited Bpss40 | 9,391,635 | 1.63% |
| Cogent Nominees Limited | 8,845,907 | 1.53% |
| Custodial Services Limited | 7,542,681 | 1.31% |
| BNP Paribas Noms Pty Ltd | 6,724,163 | 1.17% |
| National Nominees Limited | 6,379,451 | 1.11% |
| Premier Nominees Limited | 6,339,895 | 1.10% |
| FNZ Custodians Limited | 6,193,852 | 1.07% |
| Custodial Services Limited I | 5,953,253 | 1.03% |
| Jbwere (Nz) Nominees Limited | 4,596,927 | 0.80% |
Frequently Asked Questions
-
Yes. Fisher & Paykel Healthcare has paid twice yearly, unfranked dividends every year since mid-2002, the year following its initial listing on the ASX. The company paid an interim dividend of 11.48 cents per share on 19 December 2019. Fisher & Paykel Healthcare’s final dividend payment of 18.24 cents per share will be paid on 17 July 2020.
-
Fisher & Paykel Healthcare established a dividend reinvestment plan in 2009 however it has been suspended since May 2019 so is not currently in operation.